Boston Scientific study shows long-term benefits of Promus Element stent

Boston Scientific has announced positive results from a comparative study of the Promus Element everolimus-eluting platinum chromium coronary stent system lasting three years.

Data from the Platinum trial showed that the device was associated with a three-year target lesion revascularisation rate of 3.5 percent, lower than any other device previously assessed in a pivotal US Food and Drug Administration approval trial.

The stent also delivered a superior safety and efficacy performance compared to a leading rival product, thus further underlining the benefits of the Promus Element device, which has now been approved in both the US and Europe.

Kevin Ballinger, president of interventional cardiology at Boston Scientific, said: "With its outstanding deliverability, conformability and visibility, the Promus Element Stent offers interventional cardiologists an exceptional stenting option for patients with coronary artery disease."

Earlier this month, the company reported positive data from Prevail, a clinical trial assessing the advantages of its Watchman left atrial appendage closure device.